Eric Thepaut Net Worth

The estimated Net Worth of Eric Francis Yves Thepaut is at least $16.5 Milion dollars as of 10 May 2024. Mr. Thepaut owns over 12,931 units of Boston Scientific stock worth over $3,678,555 and over the last 10 years he sold BSX stock worth over $12,858,326. In addition, he makes $0 as Executive Vice President and President - Europe a Middle East and Africa at Boston Scientific.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Thepaut BSX stock SEC Form 4 insiders trading

Eric has made over 69 trades of the Boston Scientific stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 12,931 units of BSX stock worth $210,905 on 10 May 2024.

The largest trade he's ever made was selling 83,401 units of Boston Scientific stock on 2 May 2023 worth over $4,377,718. On average, Eric trades about 7,180 units every 40 days since 2015. As of 10 May 2024 he still owns at least 44,352 units of Boston Scientific stock.

You can see the complete history of Mr. Thepaut stock trades at the bottom of the page.

Eric Thepaut biography

Eric Francis Yves Thepaut serves as Executive Vice President and President - Europe, Middle East and Africa of the Company. Prior to his current role, he was senior vice president and president, Europe from January 2015 to December 2017 and served as vice president Interventional Cardiology & Structural Heart, Europe, from December 2012 to December 2015. He joined Boston Scientific Europe, in 1996, as a business finance manager and earned roles of increasing responsibility in marketing and finance including vice president, Finance, Europe, general manager and vice president, France, and general manager and vice president of the France Group, comprised of France, Benelux and Middle East North Africa. Before joining Boston Scientific, Mr. Thépaut held management positions in treasury operations and auditing at Nestlé and financial planning and analysis at Apple Computer. Mr. Thépaut earned his M.B.A. at Paris Dauphine University.

How old is Eric Thepaut?

Eric Thepaut is 58, he's been the Executive Vice President and President - Europe a Middle East and Africa of Boston Scientific since 2020. There are 7 older and 20 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.

What's Eric Thepaut's mailing address?

Eric's mailing address filed with the SEC is 300 BOSTON SCIENTIFIC WAY, , MARLBOROUGH, MA, 01752-1234.

Insiders trading at Boston Scientific

Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele a Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.

What does Boston Scientific do?

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Complete history of Mr. Thepaut stock trades at Boston Scientific

Boston Scientific executives and stock owners

Boston Scientific executives and other stock owners filed with the SEC include:

• Michael Mahoney,
  Chairman of the Board, President, Chief Executive Officer
• Daniel Brennan,
  Chief Financial Officer, Executive Vice President
• Joseph Fitzgerald,
  Executive Vice President, President, Interventional Cardiology
• Edward Mackey,
  Executive Vice President - Operations
• David Pierce,
  Executive Vice President and President, MedSurg and President, Endoscopy
• Michael F. Mahoney,
  Chairman, Pres & CEO
• Daniel J. Brennan,
  Exec. VP & CFO
• Joseph M. Fitzgerald,
  Exec. VP & Pres of Interventional Cardiology
• Edward F. Mackey,
  Exec. VP of Global Operations
• Jeffrey B. Mirviss,
  Exec. VP & Pres of Peripheral Interventions
• Edward Ludwig,
  Lead Independent Director
• Charles Dockendorff,
  Independent Director
• David Roux,
  Independent Director
• John Sununu,
  Independent Director
• Donna James,
  Independent Director
• Nelda Connors,
  Independent Director
• Ellen Zane,
  Independent Director
• Stephen MacMillan,
  Independent Director
• Yoshiaki Fujimori,
  Independent Director
• John Sorenson,
  Senior Vice President - Manufacturing and Supply Chain
• Meghan Scanlon,
  Senior Vice President and President, Urology and Pelvic Health
• Scott Olson,
  Senior Vice President and President, Rhythm Management
• Maulik Nanavaty,
  Senior Vice President and President - Neuromodulation
• Wendy Carruthers,
  Senior Vice President - Human Resources
• Desiree Ralls-Morrison,
  Senior Vice President, General Counsel, Corporate Secretary
• Jodi Eddy,
  Senior Vice President, Chief Information Officer
• Eric Thepaut,
  Executive Vice President and President - Europe, Middle East and Africa
• Jeffrey Mirviss,
  Executive Vice President and President - Peripheral Interventions
• Ian Meredith,
  Executive Vice President, Global Chief Medical Officer
• Arthur Butcher,
  Executive Vice President and President, Asia Pacific
• Catherine Jennings,
  VP of Global Marketing & New Bus. Devel. of Peripheral Interventions
• Vance R. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Susan Vissers Lisa,
  VP of Investor Relations
• Jodi Euerle Eddy,
  Sr. VP and Chief Information & Digital Officer
• Jonathan R Monson,
  VP, Global Controller & Chief Accounting Officer
• Vance R Brown,
  SVP, GC and Corp. Secretary
• Timothy A. Pratt,
  EVP & General Counsel
• Supratim Bose,
  EVP & President, Asia-Pacific
• Michael P. Phalen,
  SVP & President, Endoscopy
• Keith D Dawkins,
  Sr. VP, Chief Medical Officer
• Kevin J. Ballinger,
  EVP & Pres, Interven Cardio
• Cheryl Pegus,
  Director
• David S Wichmann,
  Director
• Xin Warren Wang,
  SVP and Pres, Asia Pacific
• Peter M Nicholas,
  Director
• Kristina M Johnson,
  Director
• Nicholas J Jr Nicholas,
  Director
• Karen Prange,
  SVP&Pres, Uro & Women's Health
• Ernest Mario,
  Director
• John E Abele,
  Director
• Uwe E Reinhardt,
  Director
• Katharine T Bartlett,
  Director
• Jean Fitterer Lance,
  SVP & Chief Compliance Officer
• Kenneth Pucel,
  EVP, Operations
• Bruce L Byrnes,
  Director
• John Michael Onuscheck,
  SVP & Pres-Neuromodulation
• Jeffrey D Capello,
  Chief Accounting Officer
• Otha T. Iii Spriggs,
  SVP, Human Resources
• William Kucheman,
  SVP & Group President
• John Raymond Elliott,
  Director
• Lawrence R Neumann,
  SVP and Pres, Emerging Markets
• John B. Pedersen,
  Pres,Uro & Women's Health
• Brian R Burns,
  SVP - Quality
• Ray J Groves,
  Director
• Sam R Leno,
  CFO & EVP Finance & IS
• Stephen F Moreci,
  Sr. VP, Endosurgery
• Marye Anne Fox,
  Director
• Fred Colen,
  EVP
• John E Pepper,
  Director
• James Gilbert,
  EVP
• Donovan Paul,
  SVP, Corporate Comm
• David W Mc Faul,
  Senior VP International
• Ursula M Burns,
  Director
• Warren B Rudman,
  Director
• William F Jr Mcconnell,
  SVP, Administration CRM
• Donald S Baim,
  EVP, Chief Med. & Sci. Officer
• Lucia Luce Quinn,
  Exec. Vice President-HR
• James R Tobin,
  President & CEO
• Paul W Sandman,
  EVP and General Counsel
• Paul A Laviolette,
  COO
• Nancy Ann Deparle,
  Director
• Joel Lawrence Fleishman,
  Director
• David C Habiger,
  Director
• Jonathan Monson,
  SVP, Global Controller and CAO
• Emily Woodworth,
  SVP, Global Controller and CAO
• Jessica L Mega,
  Director
• Susan E Morano,
  Director